Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee.
Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. Woopen H, et al. Among authors: lee yc. Cancer Treat Rev. 2022 Jun;107:102396. doi: 10.1016/j.ctrv.2022.102396. Epub 2022 May 2. Cancer Treat Rev. 2022. PMID: 35525106 Free article. Review.
To Treat or Not to Treat.
Lee YC, Davis A. Lee YC, et al. JNCI Cancer Spectr. 2019 Apr 15;3(2):pkz023. doi: 10.1093/jncics/pkz023. eCollection 2019 Jun. JNCI Cancer Spectr. 2019. PMID: 31360900 Free PMC article. No abstract available.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Lee YC, et al. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. Int J Gynecol Cancer. 2022. PMID: 35086926 Free PMC article.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, Connell RO, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT; GCIG Symptom Benefit Group. Campbell R, et al. Among authors: lee yc. Gynecol Oncol. 2022 Aug;166(2):254-262. doi: 10.1016/j.ygyno.2022.05.024. Epub 2022 Jun 17. Gynecol Oncol. 2022. PMID: 35718565
Erratum to "GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee" [Cancer Treatm. Rev. 107 (2022) 102396].
Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. Woopen H, et al. Among authors: lee yc. Cancer Treat Rev. 2022 Sep;109:102431. doi: 10.1016/j.ctrv.2022.102431. Epub 2022 Jul 5. Cancer Treat Rev. 2022. PMID: 35803179 No abstract available.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Roncolato F, King MT, O'Connell RL, Lee YC, Joly F, Hilpert F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Kaminsky MC, Stockler MR, Friedlander M. Roncolato F, et al. Among authors: lee yc. Gynecol Oncol. 2024 Feb 26;185:128-137. doi: 10.1016/j.ygyno.2024.02.025. Online ahead of print. Gynecol Oncol. 2024. PMID: 38412736 Free article.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Cohen PA, et al. Among authors: lee yc. Int J Gynecol Cancer. 2022 Apr 4;32(4):560-565. doi: 10.1136/ijgc-2021-002999. Int J Gynecol Cancer. 2022. PMID: 34551895 Clinical Trial.
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial.
Hayes S, Obermair A, Mileshkin L, Davis A, Gordon LG, Eakin E, Janda M, Beesley VL, Barnes EH, Spence RR, Sandler C, Jones T, Vagenas D, Webb P, Andrews J, Brand A, Lee YC, Friedlander M, Pumpa K, O'Neille H, Williams M; ECHO Collaborative; Stockler M; ECHO trial. Hayes S, et al. Among authors: lee yc. BMJ Open. 2023 Apr 13;13(4):e067925. doi: 10.1136/bmjopen-2022-067925. BMJ Open. 2023. PMID: 37055210 Free PMC article. Clinical Trial.
5,502 results